Behrouz Nezafat Maldonado
Biographic Data
| ID | 9803374 |
|---|---|
| NAME | Behrouz Nezafat Maldonado |
| GIVEN NAMES | Behrouz Nezafat |
| FAMILY NAME | Maldonado |
| SIGNATURE | MALDONADO B N |
| AFFILIATIONS | Oxford University Hospitals NHS Foundation Trust, Oxford, Oxfordshire, UK |
| VERIFIED | No |
| TOTAL WORKS | 1 |
| TOTAL CITATIONS | 0 |
| AUTHOR COUNT | 1 |
| EDITOR COUNT | 0 |
| FIRST PUBLICATION YEAR | 2020 |
| LATEST PUBLICATION YEAR | 2020 |
| H-INDEX | 0 |
What does ‘leave no one behind’ mean for humanitarian crises-affected populations in the Covid-19 pandemic
Background Risks of hospitalized infections associated with newer biologic agents have not been well characterized in relation to risks with anti-TNF therapy, especially in rheumatoid arthritis (RA) patients with high comorbidity burdens. Objectives To compare the risk of hospitalized infections among RA patients switching from anti-TNF therapy to rituximab (RTX), abatacept (ABA) or another anti-TNF. Methods Using data from 2002-10 from the U.S. …
No prominent works on this page.
What does ‘leave no one behind’ mean for humanitarian crises-affected populations in the Covid-19 pandemic
Background Risks of hospitalized infections associated with newer biologic agents have not been well characterized in relation to risks with anti-TNF therapy, especially in rheumatoid arthritis (RA) patients with high comorbidity burdens. Objectives To compare the risk of hospitalized infections among RA patients switching from anti-TNF therapy to rituximab (RTX), abatacept (ABA) or another anti-TNF. Methods Using data from 2002-10 from the U.S. …
Abatacept (1 works) · Cancer (1 works) · Comorbidity (1 works) · Confidence interval (1 works) · Confounding (1 works) · COVID-19 Clinical Research Studies (1 works) · Hazard ratio (1 works) · Internal Medicine (1 works) · Lymphoma (1 works) · Medicine (1 works)